BACKGROUND: The conformationally restricted polyamine analog PG-11047 has significant growth inhibitory activity against prostate and lung cancer cell lines and is currently under evaluation in several clinical trials, both alone and in combination with other drugs, for the treatment of relapsed or refractory cancer. The objective of this study was to identify the molecular signature of genes responsive to PG-11047 treatment and the biochemical effects of this drug in the HCT116 colon cancer cell line. MATERIALS AND METHODS: Gene expression analysis was performed using Affymetrix GeneChip human genome U133 Plus 2.0 arrays. Changes in protein expression were evaluated using 2D polyacrylamide gels followed by LCMS/MS. RESULTS: Treatment of cells with PG-11047 at concentrations ranging from 0.1 to 10 microM caused inhibition of cell growth. The activity of PG-11047 was found to correlate with its transcriptional effects on cell cycle control, focal adhesion, adherent and gap junction genes, MAPK-, Wnt- and, TGF-beta signaling pathways, transport and DNA/RNA transcription factor genes. PG-11047 caused depletion of polyamine pools. Proteomics analysis showed that PG-11047 restricts the modification of eukaryotic translation initiation factor 5A (eIF5A), resulting in suppression of general protein synthesis in PG-11047-treated cells. CONCLUSION: These data show that PG-11047 has a broad spectrum of anticancer activity in colon cancer cells.
BACKGROUND: The conformationally restricted polyamine analog PG-11047 has significant growth inhibitory activity against prostate and lung cancer cell lines and is currently under evaluation in several clinical trials, both alone and in combination with other drugs, for the treatment of relapsed or refractory cancer. The objective of this study was to identify the molecular signature of genes responsive to PG-11047 treatment and the biochemical effects of this drug in the HCT116colon cancer cell line. MATERIALS AND METHODS: Gene expression analysis was performed using Affymetrix GeneChip human genome U133 Plus 2.0 arrays. Changes in protein expression were evaluated using 2D polyacrylamide gels followed by LCMS/MS. RESULTS: Treatment of cells with PG-11047 at concentrations ranging from 0.1 to 10 microM caused inhibition of cell growth. The activity of PG-11047 was found to correlate with its transcriptional effects on cell cycle control, focal adhesion, adherent and gap junction genes, MAPK-, Wnt- and, TGF-beta signaling pathways, transport and DNA/RNA transcription factor genes. PG-11047 caused depletion of polyamine pools. Proteomics analysis showed that PG-11047 restricts the modification of eukaryotic translation initiation factor 5A (eIF5A), resulting in suppression of general protein synthesis in PG-11047-treated cells. CONCLUSION: These data show that PG-11047 has a broad spectrum of anticancer activity in colon cancer cells.
Authors: Sheila A Bingham; Nicholas E Day; Robert Luben; Pietro Ferrari; Nadia Slimani; Teresa Norat; Françoise Clavel-Chapelon; Emmanuelle Kesse; Alexandra Nieters; Heiner Boeing; Anne Tjønneland; Kim Overvad; Carmen Martinez; Miren Dorronsoro; Carlos A Gonzalez; Timothy J Key; Antonia Trichopoulou; Androniki Naska; Paolo Vineis; Rosario Tumino; Vittorio Krogh; H Bas Bueno-de-Mesquita; Petra H M Peeters; Göran Berglund; Göran Hallmans; Eiliv Lund; Guri Skeie; Rudolf Kaaks; Elio Riboli Journal: Lancet Date: 2003-05-03 Impact factor: 79.321
Authors: Frank L Meyskens; Christine E McLaren; Daniel Pelot; Sharon Fujikawa-Brooks; Philip M Carpenter; Ernest Hawk; Gary Kelloff; Michael J Lawson; Jayashri Kidao; John McCracken; C Gregory Albers; Dennis J Ahnen; D Kim Turgeon; Steven Goldschmid; Peter Lance; Curt H Hagedorn; Daniel L Gillen; Eugene W Gerner Journal: Cancer Prev Res (Phila) Date: 2008-06
Authors: Malcolm A Smith; John M Maris; Richard Lock; E Anders Kolb; Richard Gorlick; Stephen T Keir; Hernan Carol; Christopher L Morton; C Patrick Reynolds; Min H Kang; Peter J Houghton Journal: Pediatr Blood Cancer Date: 2011-02-25 Impact factor: 3.167
Authors: Tracy Murray Stewart; Apurva A Desai; Michael L Fitzgerald; Laurence J Marton; Robert A Casero Journal: Cancer Chemother Pharmacol Date: 2020-05-23 Impact factor: 3.333
Authors: Tracy Murray-Stewart; Christin L Hanigan; Patrick M Woster; Laurence J Marton; Robert A Casero Journal: Mol Cancer Ther Date: 2013-08-13 Impact factor: 6.261
Authors: Tracy Murray-Stewart; Elena Ferrari; Ying Xie; Fei Yu; Laurence J Marton; David Oupicky; Robert A Casero Journal: PLoS One Date: 2017-04-19 Impact factor: 3.240
Authors: Diptesh Sil; Sudipta Panja; Chinmay M Jogdeo; Raj Kumar; Ao Yu; Cassandra E Holbert; Ling Ding; Jackson R Foley; Tracy Murray Stewart; Robert A Casero; David Oupický Journal: Molecules Date: 2022-04-10 Impact factor: 4.927
Authors: Wen-Lin Kuo; Debopriya Das; Safiyyah Ziyad; Sanchita Bhattacharya; William J Gibb; Laura M Heiser; Anguraj Sadanandam; Gerald V Fontenay; Zhi Hu; Nicholas J Wang; Nora Bayani; Heidi S Feiler; Richard M Neve; Andrew J Wyrobek; Paul T Spellman; Laurence J Marton; Joe W Gray Journal: BMC Med Date: 2009-12-14 Impact factor: 8.775
Authors: Tracy Murray Stewart; Daniel Von Hoff; Michael Fitzgerald; Laurence J Marton; Carlos H Roberto Becerra; Thomas E Boyd; Paul R Conkling; Lawrence E Garbo; Robert M Jotte; Donald A Richards; David A Smith; Joe J Stephenson; Nicholas J Vogelzang; Hillary H Wu; Robert A Casero Journal: Cancer Chemother Pharmacol Date: 2020-11-19 Impact factor: 3.333